<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04666961</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-2020-06</org_study_id>
    <nct_id>NCT04666961</nct_id>
  </id_info>
  <brief_title>Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ</brief_title>
  <acronym>HORNEO01</acronym>
  <official_title>Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast&#xD;
      cancer cases. Of these women, 20% require radical management in the form of mastectomy&#xD;
      because of the extent of the lesions, which most often manifest as diffuse&#xD;
      microcalcifications.&#xD;
&#xD;
      This mutilating surgical management contrasts with the excellent prognosis of this pathology&#xD;
      and considerably alters the quality of life of patients.&#xD;
&#xD;
      Neoadjuvant hormone therapy has shown its efficacy in hormone-dependent infiltrating ductal&#xD;
      carcinomas and offers the possibility of conservative surgery after hormone therapy.&#xD;
&#xD;
      Adjuvant hormone therapy with Tamoxifen or anti-aromatase drugs has shown its efficacy in the&#xD;
      prevention of homo or contralateral recurrence.&#xD;
&#xD;
      The HORNEO 01 trial fits perfectly in the current context of surgical de-escalation of ductal&#xD;
      carcinomas in situ. The objective of the study is to evaluate the impact of neoadjuvant&#xD;
      hormone therapy on the surgical management of extensive DCIS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Description of the modalities for recruiting :&#xD;
&#xD;
      Following screening and discovery of a DCIS, patients are referred to the center for surgical&#xD;
      management.&#xD;
&#xD;
      During a standard consultation, the surgeon presents the study to the patient who has been&#xD;
      diagnosed with extensive DCIS with an indication for mastectomy. The surgeon provides the&#xD;
      patient with the information note and the consent form to participate in the study. Once the&#xD;
      consent form is signed by the patient and the investigator, the investigator prescribes a&#xD;
      screening test to be performed within 30 days prior to the start of hormone therapy.&#xD;
&#xD;
      Screening assessment includes :&#xD;
&#xD;
      A clinical exam and a breast imaging exam (mammography and breast and axillary ultrasound).&#xD;
      In case of a suspicious breast ultrasound image, microbiopsy will be performed to eliminate&#xD;
      an infiltrating component.&#xD;
&#xD;
      One or more macrobiopsy. Each biopsied site will be located using an X-ray clip inserted at&#xD;
      the time of sample.&#xD;
&#xD;
      A MRI post-macrobiopsy. Research of estrogen receptor expression&#xD;
&#xD;
      Once the investigator has verified and validated all the eligibility criteria, the patient&#xD;
      will be included.&#xD;
&#xD;
      Prescriptions for Tamoxifen (non-menopausal patients) or Anastrozole (menopausal patients)&#xD;
      are given to patients and dispensed by the center's pharmacy.&#xD;
&#xD;
      Monitoring during treatment :&#xD;
&#xD;
      Patients will benefit from imaging monitoring (Mammography, +/- breast ultrasound, +/-&#xD;
      axillary ultrasound, MRI) at 3 months and 6 months during hormonotherapy.&#xD;
&#xD;
      In case of progression observed during treatment, hormone therapy will be stopped and you&#xD;
      will then benefit from a mastectomy.&#xD;
&#xD;
      Surgery :&#xD;
&#xD;
      Mastectomy or tumorectomy will be performed according to the tumor response to hormone&#xD;
      therapy observed on MRI.&#xD;
&#xD;
      All patients will benefit sentinel node detection. An additional axillary dissection will be&#xD;
      performed based on the results of the sentinel node analysis.&#xD;
&#xD;
      Analysis of biomarkers and tumor microenvironment before and after treatment on diagnostic&#xD;
      macrobiopsies and on tumorectomy or mastectomy will be performed at Institut de Cancérologie&#xD;
      de l'Ouest.&#xD;
&#xD;
      Patients will be seen in postoperative consultation. Adjuvant treatments or re-surgical&#xD;
      interventions will be prescribed, carried out, and the patients will be followed up and&#xD;
      examined at 6 months after surgery or at the end of adjuvant treatments and then annually for&#xD;
      10 years (with control mammography).&#xD;
&#xD;
      Patients who have had conservative surgery will have an MRI at 6 months from the end of&#xD;
      radiotherapy.&#xD;
&#xD;
      All patients will be asked to complete quality of life questionnaires at baseline, 6 and 12&#xD;
      months post-surgery, and annually for 9 years:&#xD;
&#xD;
      EORTC QLQ-C30 (up to 5 years only), Short Form (36) Health Survey questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2033</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients with extensive ductal carcinoma in situ with an indication for mastectomy receiving neoadjuvant hormone therapy with Tamoxifen (non-menopausal patients) or Anastrozole (postmenopausal patients)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of neoadjuvant hormonotherapy</measure>
    <time_frame>6 months of hormonotherapy</time_frame>
    <description>% of conservative surgeries performed after hormonotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>5 and 10 years post-surgery</time_frame>
    <description>DFS rates at 5 and 10 years post-surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 and 10 years post-surgery</time_frame>
    <description>Survival rates at 5 and 10 years post-surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Complete Response (pCR)</measure>
    <time_frame>6 months of hormonotherapy</time_frame>
    <description>Pathologic complete response is defined as no residual invasive cancer in the surgical specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of response</measure>
    <time_frame>3 and 6 months of hormonotherapy</time_frame>
    <description>Response is defined by the variation in the diameter of the longest dimension of the target lesion measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Qol)</measure>
    <time_frame>At baseline, at 6 months and 12 months post-surgery, and then each year for 4 years</time_frame>
    <description>EORTC QLQ-C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Qol)</measure>
    <time_frame>At baseline, at 6 months and 12 months post-surgery, and then each year for 9 years</time_frame>
    <description>SF-36 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">262</enrollment>
  <condition>Ductal Carcinoma in Situ</condition>
  <condition>Extensive Disease</condition>
  <condition>Mastectomy</condition>
  <arm_group>
    <arm_group_label>Extended ductal carcinoma in situ with mastectomy indication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 6 months of tamoxifen or anastrozole in a neoadjuvant situation.&#xD;
Tamoxifen and Anastrozole will be delivered in their original packaging at J0 and M3 :&#xD;
Tamoxifen: box of tablets dosed at 20 mg&#xD;
Anastrozole: box of tablets 1 mg. Tamoxifen will be initiated in premenopausal patients orally at a standard dose of 20mg/day as a single dose for 6 months.&#xD;
Anastrozole will be administered orally to postmenopausal patients at the standard dose of 1mg/day in a single dose for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen 20 mg</intervention_name>
    <description>Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.</description>
    <arm_group_label>Extended ductal carcinoma in situ with mastectomy indication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole 1Mg Tab</intervention_name>
    <description>Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.</description>
    <arm_group_label>Extended ductal carcinoma in situ with mastectomy indication</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient ≥ 40 years old&#xD;
&#xD;
          2. Histological diagnosis of ductal carcinoma in situ without infiltrating contingent&#xD;
&#xD;
          3. Clinical T0N0&#xD;
&#xD;
          4. Estrogen receptor positive (OR+) regardless of progesterone receptor (PR) status&#xD;
&#xD;
          5. Indication for mastectomy&#xD;
&#xD;
          6. DCIS visible on MRI performed with clip sequence&#xD;
&#xD;
          7. Effective contraceptive method for women of childbearing age who are sexually active&#xD;
             and who have reported sexual activity.&#xD;
&#xD;
          8. Informing the patient and obtaining free, informed and written consent signed by the&#xD;
             patient and the investigator.&#xD;
&#xD;
          9. Affiliated patient or beneficiary of the social security system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Invasive breast carcinoma&#xD;
&#xD;
          2. Lobular carcinoma in situ&#xD;
&#xD;
          3. pN+ patient&#xD;
&#xD;
          4. Indication for conservative surgery&#xD;
&#xD;
          5. Contraindications to anastrozole or tamoxifen&#xD;
&#xD;
          6. Concomitant treatments that may interact and reduce the efficacy of tamoxifen by&#xD;
             interaction with cytochrome CYP2D6.&#xD;
&#xD;
          7. Histologically proven multifocal lesion&#xD;
&#xD;
          8. Contraindication to breast MRI (pace maker, heart valve, metallic implant, neuronal or&#xD;
             peripheral stimulator, severe claustrophobia, ...)&#xD;
&#xD;
          9. History of homolateral breast cancer&#xD;
&#xD;
         10. Ongoing contralateral breast cancer&#xD;
&#xD;
         11. Known mutation BRCA1 BRCA2&#xD;
&#xD;
         12. Other cancer in progress at inclusion&#xD;
&#xD;
         13. Pregnant woman, or breastfeeding,&#xD;
&#xD;
         14. Persons deprived of liberty or under guardianship or trusteeship,&#xD;
&#xD;
         15. Impossibility to undergo the medical follow-up of the trial for geographical, social,&#xD;
             psychic or psychiatric reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victoire BRILLAUD-MEFLAH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de l'Ouest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victoire BRILLAUD-MEFLAH, MD</last_name>
    <phone>0240679818</phone>
    <phone_ext>+33</phone_ext>
    <email>Victoire.brillaud-meflah@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie DEBEAUPUIS</last_name>
    <phone>0240679844</phone>
    <phone_ext>+33</phone_ext>
    <email>emilie.debeaupuis@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augustin REYNARD, MD</last_name>
      <email>paugustin.reynard@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Augustin REYNARD, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie AURIOL-LEIZAGOYEN, MD</last_name>
      <email>s.auriol@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie AURIOL-LEIZAGOYEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian GUTOWSKI, MD</last_name>
      <email>marian.gutowski@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie GOSSET, MD</last_name>
      <email>marie.gosset@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Site de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enora LAAS, MD</last_name>
      <email>enora.laas@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Enora LAAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Séverine ALRAN, MD</last_name>
      <email>Salran@hpsj.fr</email>
    </contact>
    <investigator>
      <last_name>Séverine ALRAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoire BRILLAUD-MEFLAH, MD</last_name>
      <email>Victoire.brillaud-meflah@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Victoire BRILLAUD-MEFLAH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT-O</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle SELMES, MD</last_name>
      <email>selmes.gabrielle@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Gabrielle SELMES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant hormonotherapy</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Anastrozole</keyword>
  <keyword>conservative surgery</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>extensive microcalcifications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

